Yuan Cheng and colleagues first demonstrated the ability of actin polymerization-promoting drugs to inhibit the Hippo signaling pathway and promote organ growth, and showed that disruption of Hippo signaling in ovarian follicles can be used for infertility treatment, and in mammals, the Hippo pathway has four core components, including the serine/threonine kinase MST1/2 (homologue of Hippo/Hpo) (48, 49). The gene discussed is MARK2; the disease is Infertility.